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Renal osteodystrophy (ROD) is a multifactor
disorder of bone remodelling observed in pa-
tients with chronic renal failure (CRF) from very
early stages (CRF stage 2) and associated with
significant morbidity1.
The remodelling cycle in normal bone lasts
from four to eight months and includes several
phases: 1) An activation phase in which osteo-
clasts are mobilized and activated; 2) A resorp-
tion phase in which osteoclasts erode the bone
surface; 3) A reversal phase that ends resorption
and osteoblasts are recruited to the eroded sur-
faces; 4) Unmineralized matrix (osteoid) syn-
thesised by osteoblasts; and 5) Mineralization
of the osteoid tissue. Each of these steps (or
several of them) are frequently compromised in
uraemic patients1,2.
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Bone histology remains the gold standard for
the diagnosis of renal osteodystrophy and the
distinction between high and low bone turnover
disease in these patients, frequently requires
invasive and costly methods such as bone
histomorphometry (including static and kinetic
variables after double tetracycline labelling)3,4.
Even though the bone biopsy has been
proved to be a safe procedure and one which is
free from major complications (incidence lower
than 0.7 %)5, it has been less performed over
the last decade due to several reasons (high
cost, difficult in finding experienced teams and
appropriate laboratory facilities, etc.). In our ex-
perience, with almost five hundred bone biop-
sies performed, we report less than 0.3 % of
(minor) morbidity.
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Over the last few years, the use of new thera-
peutic approaches to ROD (namely the use of
sevelamer, lanthanum carbonate, vitamin D
analogs and calcimimetics) induced an in-
creased relevance of bone histomorphometry.
In fact, these therapies have to be validated at
the bone level, and an eventual compromise of
the bone mineralization has to be excluded.
But a bone biopsy gives only a picture of the
bone lesions at the time that it is performed. It
has limitations in the long-term evaluation of the
bone turnover, and as an invasive procedure
cannot be repeated frequently. Due to these rea-
sons, in clinical practice, less invasive ap-
proaches to the diagnosis of ROD were deve-
loped.
In recent years, some biochemical markers
of bone turnover have been used and tested in
the evaluation of bone remodelling in uraemic
patients, and their use individually or in combi-
nation with other methods will improve the diag-
nosis of ROD in these patients.
In addition to these serum markers, the role
of ß2-microglobulin and of some local media-
tors involved in the process of bone cells acti-
vation and inhibition (such as cytokines and their
inhibitors) will be evaluated.
As discussed below, the best approach to
the diagnosis of ROD is the dynamic integra-
tion of different non-invasive markers of bone





Apart from a quantitative assessment of the
cellular elements directly involved in bone turno-
ver, the evaluation of bone histology provides
qualitative information on bone tissue structure
and organization (trabecular and cortical) and
also of the intra-trabecular space where eryth-
ropoiesis takes place. Bone biopsy also allows
the quantification and localization of the alu-
minium and iron bone deposits6.
The spectrum of bone changes observed in
the uraemic patient, extend from high remodel-
ling bone disease (frequently known as osteitis
fibrosa) to low turnover or adynamic disease.
Between these two histological diagnoses there
are situations of bone mineralization compro-
mise in variable degrees, as is the case of
“mixed bone disease” and osteomalacia.
Osteitis fibrosa or predominant hyperparathy-
roid bone disease is characterised by a high
bone formation rate (BFR) (high extension of the
trabecular surfaces presenting simple or dou-
ble tetracycline labels), an increased number of
osteoblasts, osteoclasts and eroded surfaces.
A marked increase in the bone marrow fibrosis
and osteoid surface is usually present.
Mixed uraemic osteodystrophy - typified by
signs of secondary hyperparathyroidism with,
in addition, increased volume and thickness of
osteoid volume is a high subjective diagnosis
and usually difficult to interpret by the clinicians.
Normally this diagnosis is found in hyperpara-
thyroid bone associated with a compromise of
mineralization (ex: vitamin D deficiency, alu-
minium overload).
Low turnover osteomalacia is characterised
by a low BFR associated with an increase in
surface, volume and thickness of osteoid.
Finally, adynamic bone disease is character-
ised by a defect of bone formation, with a
marked decrease in active remodelling sites and
a low BFR. The prevalence of adynamic bone
disease in dialysis patients has been described,
through the last decade, as reaching between
15% and 60% of the patients1,6,7. This wide range
can be attributed to a different patient criteria
selection, differences in the usage of aluminium
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to establish the diagnosis of ROD disease in
symptomatic patients, when the non-invasive
markers discussed below are not enough.  Af-
ter kidney transplantation this invasive diagno-
sis can be particularly relevant to differentiate
ROD from the bone effects of the immunosup-
pressive drugs.
As already mentioned, a significant increase
in bone biopsies performed in uraemic patients
has been observed during the last years, as part
of research protocols to validate new ROD
therapies.
Serum markers of bone turnover
We are still looking for a specific and sensi-
tive serum biochemical test for monitoring bone
turnover in uraemia. In fact, the ideal biochemi-
cal marker of bone turnover should be unique to
bone, reflect total skeletal activity and well cor-
related with histomorphometric and radiocal-
cium kinetics results.
Several enzymes and matrix proteins syn-
thesised by osteoblasts, and some protein frag-
ments released after bone matrix breakdown
during the resorption process, have been pro-
posed as serum biochemical markers of bone
formation (bone-specific alkaline phosphatase
- bAP; osteocalcin – OC; procollagen type I
carboxy-terminal extension peptide – PICP), and
of bone resorption (tartrate-resistant  acid phos-
phatase – TRAP; Type I collagen cross-linked
telopeptide – ICTP; Pyridinoline cross-links of
collagen – Pyr and Dpyr) (Table I).
Unfortunately, the interpretation of serum or
plasma levels of these markers is hindered in
CRF by different factors (circadian rhythms, diet,
age, sex, menopause, liver function, clearance
rates, type of dialysis membrane, ultrafiltration,
etc.).
As bone remodelling results from the combi-
versus nom-metal based phosphate binders,
inappropriate treatment of tap water, different
dialysis membranes, variable usage of vitamin
D metabolites, etc.
Adynamic disease appears more frequently
in diabetic and elderly patients, with a prevalence
of between 30 and 50% of biopsied patients.  In
most cases, it is of iatrogenic nature, resulting
from previous parathyroidectomy surgery or ex-
cess calcium and/or vitamin D therapy. Alumi-
nium exposure, although progressively more
rare, is still a cause of low turnover bone disease6,8.
Almost ten years ago, aluminium overload
was still the most frequent cause of adynamic
bone disease in Iberoamerican countries, as
was shown by our group in a review of 1209
bone biopsies from symptomatic patients6,9. In
fact, at that time, two thirds of the patients from
Portugal and Spain with adynamic bone disease
had a solochrome stainable bone surface alu-
minium higher then 25%. In our personal expe-
rience from the last 3-5 years (still not published)
the prevalence of aluminium deposits in bone
has decreased significantly.
The suspicion of aluminium overload may be
established by the patient dialysis history (wa-
ter treatment and type of phosphate binders),
by the plasma aluminium levels (that have to be
interpreted simultaneously with the iron status
by measurement of plasma ferritin10 and by the
presence of a positive desferroxamine test (in-
crease of plasma aluminium superior to 50 mg/
L after administration of 5 mg/Kg of desferrioxa-
mine).  In the presence of a significant aluminium
exposition a bone biopsy seems indicated at
least: 1) prior to parathyroidectomy, (since low
turnover bone disease may be precipitated 2)
and before starting long term desferrioxamine
treatment, which is not devoid of hazards (i.e.
deafness, fatal mucormycosis)11.
Besides these indications for an invasive dia-
gnosis, a bone biopsy may have to be performed
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nation of bone formation and bone resorption, it
is particularly difficult to evaluate separately
these two processes through the serum levels
of some biological markers. In fact, this is the
major limitation to the use of intact parathyroid
hormone (iPTH) in the evaluation of bone re-
modelling: we cannot obtain information from the
bone formation and bone resorption separately.
Measurement of plasma parathyroid
hormone and bone turnover
Parathyroid hormone (PTH) is a molecule of
84 amino acids that controls bone turnover. In
addition to the intact molecule, PTH fragments
containing carboxy-terminal parts of varying
length are also present in the circulation. In 1987
an IRMA assay that measured PTH by “san-
dwiching” it between two antibodies was deve-
loped.  This first generation IRMA – PTH assay,
known as “intact PTH assay”, was intended to
be free of PTH interference and became the
standard in research and clinical practice12,13.
The development of these (IRMA) assays for
intact parathyroid hormone (iPTH), has shown
that measurement of iPTH levels is a useful pre-
dictor of bone histology and can be used as a
non-invasive tool in distinguishing between high-
turnover (HTBD) and normal or low-turnover
bone disease (N/LTBD) when groups of patients
are considered14.
However, on an individual patient, serum iPTH
levels alone are frequently not able to distinguish
adynamic bone from hyperparathyroid bone di-
sease, as was demonstrated by Qi et al15. Ac-
cording to the results of this group, the iPTH le-
vels between 65 and 450 pg/ml could not predict
the bone turnover in dialysis patients, and an in-
vasive diagnosis was proposed for these patients.
The data from Gerakis et al. shows that
plasma iPTH values below 65 pg/ml, in patients
with end stage renal disease, have a poor posi-
tive predictive value (45%) in the diagnosis of
adynamic bone disease, but present an excel-
lent negative predictive level, even in patients
with significant aluminium bone deposition16.
Concerning the diagnosis of HTBD the same
authors obtained a positive predictive value of
97% when a value of iPTH 3.5 times above the
upper limit of normal, was considered. This posi-
tive predictive value dropped to 78% in the pre-
sence of aluminium staining.
Subsequently, Quarles et al. reported that
iPTH assay still showed clinical evidence of frag-
ment interference by overestimating bone turno-
ver17.
In 1998, D’Amour et al. demonstrated that
iPTH assay did not measure only full length 1-84
PTH as is was intended, but also measured a 7-
84 PTH fragment18. One year later, a “second
Biochemical markers of bone turnover in uraemic patients
1. Bone remodelling
a. Intact parathyroid hormone (iPTH)
b. “Whole” parathyroid hormone; Cyclase activating
PTH (whole PTH)
2. Bone formation
a. Total alkaline phosphatase (tAP)
b. Bone alkaline phosphatase (bAP)
c. Osteocalcin or GLA protein (BGP)
d. Procollagen type I carboxy-terminal extension
propeptide (PICP)
3. Bone resorption
a. Tartrate-resistant acid phosphatase (TRAP)
b. Pyridinoline cross-links (Pyr; Dpyr)
c. Type I collagen cross-linked telopeptide ICTP
d. ß2-microglobulin (ß2M)
4. Cytokines and growth factors involved in bone
remodelling
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generation” immunoradiometric two-site san-
dwich assay was developed, which seems to ex-
clusively detect the biological active 1-84 PTH.
This new assay called “whole” PTH - CAP
(Cyclase activating PTH) makes use of an anti-
body directed to the carboxy-terminal part of
PTH and another radiolabeled anti-body directed
to the first amino-acids of the amino-terminal
part of the molecule.
The second generation PTH assays  (Whole
PTH-CAP from Scantibodies or Bio-intact PTH
from Nichols) apparently do not measure a PTH
molecule that lacks the first amino-acids nor
those PTH fragments, amino-terminally trun-
cated, which are measured by the first genera-
tion intact PTH assays19.
One of the most relevant amino-terminally
truncated PTH fragment seems to be the 7-84
PTH, which seems to operate through a differ-
ent PTH receptor that does not activate ade-
nylate cyclase (7-84 PTH is also called Cyclase
Inactive PTH or CIP)20,21.
The 7-84 PTH fragment is present in the cir-
culation of ESRD patients, but is also produced
by the parathyroid glands of normal subjects.
This fragment seems to inhibit bone resorption
and the activation of osteoclasts and osteoblasts
in vitro and in vivo22,23. If these results are con-
firmed with consistent histomorphometric data,
1-84 PTH and 7-84 PTH should be considered
as two hormones with opposing biological ac-
tions.
According to the recently published Silver-
berg and co. research, the second generation
PTH assays were 24% more accurate in the
diagnosis of primary hyperparathyroidism than
the iPTH assay24. In CRF, these “whole” PTH
assays appear to present with values that are
approximately half of those achieved with the
“intact” PTH assays25.
Some authors postulated that the ratio of 1-
84 PTH / 7-84 PTH is helpful in the diagnosis of
adynamic bone disease26, but these results were
not reproduced by others.
In a paediatric population of 33 patients
treated with peritoneal dialysis, first and second
generation immunometric PTH assays showed
a similar predictive value of bone turnover and
both were best predictors of bon formation than
the ratio 1-84 PTH / 7-84 PTH27.
In a recent review from three published stud-
ies focused on the relationship between bone
histology and plasma PTH levels, as evaluated
by first and second generation IRMA PTH as-
says, Goodman concluded that both assays are
highly correlated and have a similar diagnostic
value28.
Other PTH fragments of PTH with structural
integrity of the (1-4) region but modified in the
(15-20) region were recently described by
D’Amour, but the clinical implications of these
fragments remain to be defined in the uraemic
patient29.
 The interpretation and significance of PTH
levels, independently of the method of determi-
nation, in the individual patient is further compli-
cated by other factors, such as the resistance
of skeletal to PTH during the evolution of the
chronic renal failure, postulated by Massry30  and
demonstrated by our group, in the epiphyseal
cartilage growth plate of uraemic rats31.
It is clear that, in addition to PTH, other tests
or new markers of bone remodelling are needed
in order to permit a correct and dynamic non-
invasive diagnosis of bone turnover. These bio-
chemical markers have to be compared and
combined with PTH plasma values to evaluate
their additional interest.
Biochemical markers of bone formation
Until now, six alkaline phosphatase isoen-
zymes, produced by different organs have been
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identified: liver, bone, kidney, intestine and pla-
centa and tumoral32-35. Interestingly, one single
gene codes for alkaline phosphatase (AP), and
the isoforms differ only by post-transcriptional
glycosilation36.
Bone AP (bAP) is produced by osteoblasts
and osteoblasts precursors, and participates in
bone formation and in the mineralization pro-
cess. This molecule provides a high phosphate
concentration at the osteoblastic surface and
catalyses the hydrolysis of pyrophosphate (an
inhibitor of mineralization, that is reduced through
this reaction)37.
The bAP molecule has a molecular weight
of 80Kda and as is neither dialyzable nor re-
moved by the kidneys, and its plasma levels are
not affected by the renal function38. These cha-
racteristics of bAP are particularly relevant in the
evaluation of renal osteodystrophy.
Several laborious and time-consuming tech-
niques have been used to select for the osteob-
last enzyme, bone specific alkaline phos-
phatase (bAP) and to enhance the sensitivity of
this marker, including heat inactivation, wheat
germ lectin or concavalin-A precipitation, inhibi-
tion by amino acids and urea, high-performance
affinity chromatography and agarose gel elec-
trophoresis. The development of monoclonal
antibodies specific for bAP have been used in
radioimmunological tests (which measure the
mass of bAP) and in immunoenzimatic assays
(which measure the activity of the isoenzime),
providing the basis for a more specific index of
bone formation39.
In 42 haemodialysis patients, we showed that
plasma bAP levels (measured with a new di-
rect immunoradiometric assay - IRMA) were
better correlated with bone formation and bone
resorption histomorphometric parameters than
iPTH or total AP levels40. Values of bAP higher
than 20 ng/ml had a sensitivity of 100% and a
specificity of 100% for the diagnosis of HTBD
and there was an excellent correlation between
plasma bAP levels and the bone formation rate
(BFR). When these limits of bAP values were
associated with iPTH serum levels > 200 pg/ml,
the positive predictability value for the diagnosis
of HTBD increased from 84% to 94%. These
results have been confirmed by other groups
not only in HTBD patients41, but also in the diag-
nosis of adynamic bone disease (ABD) by
Couttenye et al., in the latter case by using the
agarose-gel electrophoresis method for detec-
tion of low levels of plasma bAP42.
If a plasma bAP higher than 20 ng/ml, ac-
cording to our results40, (confirmed by other
studies43), formally excludes the presence of a
low bone turnover disease, we could not define
a plasma bAP concentration predictive of ady-
namic bone disease. It still needs to be demons-
trated that BAP is sensitive enough to distinguish
between low versus normal bone turnover, and
the results from Fletcher et al.43 demonstrated
that the non-invasive markers of bone turnover,
including bAP, were unable to distinguish be-
tween low-turnover bone disease, normal bone
and mild osteitis fibrosa.
In pre-dialysis end-stage renal patients, bAP
demonstrated a high positive predictive value
(PPV) of 89% but only if adynamic and normal
bone were taken together as one group44. In
these pre-dialysis patients the combination of
an osteocalcin level of 41 ng/L or less with a
bAP serum level of 23 U/L or less increased the
PPV in the diagnosis of adynamic bone to 77%44.
The dissociation between plasma iPTH and
plasma bAP levels, frequently observed in urae-
mic patients may have several explanations and
different causes:
- PTH reflects the parathyroid function and bAP
the osteoblasts activity. An increase in
plasma PTH is not always indicative of high
bone turnover disease;
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- The presence of aluminium overload may be
responsible for the association of high bAP
(due to a direct osteblast stimulation) with low
iPTH (resulted from an inhibition of PTH syn-
thesis and release)45,46;
- This year, we published our results on a dia-
lysis population of 140 dialysed patients, con-
firming that higher serum aluminium levels
were associated with a significant decrease
in the concordance between plasma bAP and
iPTH serum levels47.
- After successful kidney transplantation
plasma iPTH returns to normal in more than
80% patients, but bAP shows a tendency to
increase, probably because of an increase
in bone turnover48,49. A similar dissociation
can frequently be seen in the “hungry bone
syndrome” after parathyroidectomy;
- As already discussed in this review, first ge-
neration IRMA iPTH assays could overesti-
mate the concentration of active PTH and
also contribute to the dissociation with bAP
plasma levels;
- In recent years, an uncoupling between bone
formation and bone resorption has been re-
ported with apparently increasing frequency
by several researchers, which could explain
that high PTH levels could be associated pre-
dominantly with osteoclasts activity and with
normal or low bAP levels50.
In summary, plasma bAP in combination with
plasma PTH levels increases the sensitivity and
specificity in the diagnosis of bone remodelling in
uraemic patients. But the clinician has to remem-
ber that several conditions can be responsible for
the discordance between the levels of these two
biochemical markers. In the individual evaluation
of a patient all those conditions have to be con-
sidered, and bone histomorphometry appears to
still be indispensable in some situations.
Osteocalcin or GLA protein (BGP) repre-
sents one of the most abundant non-collagen-
ous bone proteins, that is also present in dentin
and calcified cartilage. It is produced by osteo-
blasts and odontoblasts under the control of
1.25-OH2D3 and has been regarded as a marker
of bone formation. The carboxylation of this pro-
tein depends on vitamin K, as a cofactor of the
reaction, and has a half-life of approximately five
minutes. The deficit in vitamin K and the de-
crease in osteocalcin levels have been associ-
ated with a decrease in bone mass and a high
fracture risk51;52. Even though the association
of bone formation with osteocalcin activity is
supported by several results, the physiological
role of osteocalcin is still not completely under-
stood. For instance, the knock-out mice for
osteocalcin present a significant increase in
bone formation and bone density53.
Osteocalcin concentrations have been dem-
onstrated to have a significant positive correla-
tion with osteoblastic surface and bone forma-
tion rate, in the normal population and in uraemic
patients54,55.
Serum intact osteocalcin seems to reflect the
excess of produced protein not integrated in bone
matrix, or resulting from the process of bone
resorption.
The major problem in determining osteocal-
cin levels by conventional radio immunoassays
is distinguishing intact osteocalcin from inactive
fragments that accumulate in renal failure. To
overcome this problem, a sandwich immuno-
assay that only detects the intact molecule of
serum osteocalcin was developed56.
These new immunoradiometric assays,
which use specific monoclonal antibodies to mea-
sure only intact osteocalcin may be more accu-
rate, (since they will exclude BGP fragments),
but they still measure 3 different molecules of
unknown significance: total osteocalcin, carboxy-
lated and decarboxylated osteocalcin.
In uraemic patients circulating intact osteo-
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calcin represents less than one third of the total
osteocalcin. The remaining two thirds corres-
pond to N-terminal, C-terminal and midregion
osteocalcin fragments57. The biological role of
these fragments that accumulate in chronic re-
nal failure is still not clarified.
 Osteocalcin also suffers from poor stability
and is removed via the kidneys. After meno-
pause its serum levels increased less that those
of bAP, showing lower sensitivity and inferior
sensibility in the diagnosis of bone turnover in
this osteopathy58.
In pre-dialysis end stage renal patients,
osteocalcin had a positive predictive value (PPV)
in the diagnosis of adynamic of only 47%44.
In spite of these limitations, in our experience
the plasma osteocalcin concentration showed
a good sensitivity in distinguishing between high
turn-over bone disease versus normal-low bone
turn-over. The values were 555 versus 198 ng/
mL, respectively59. As seen with other biochemi-
cal markers of bone turnover the sensitivity of
osteocalcin was much lower in the differentia-
tion between low turn-over bone disease and
normal bone remodelation.
In a recent work from Morishita on 62 haemo-
dialysis patients who underwent a bone biopsy,
the optimal cut-off value to distinguish adynamic
bone disease from a mild lesion was 195 pg/
mL of serum iPTH or 30 ng/mL of serum intact
osteocalcin and the optimal cut-off value to dis-
tinguish between hyperparathyroid bone and a
mild lesion was 455 pg/mL of serum iPTH or 50
ng/mL of intact osteocalcin concentration60.
Although weaker than bAP and iPTH, the
correlations of plasma osteocalcin with bone
histomorphometric parameters (especially of
bone formation and bone mineralization), in
haemodialysis patients were quite good59.
Procollagen type I carboxy-terminal exten-
sion propeptide (PICP), has a molecular weight
of approximately 100.000 Da and has been used
as serum marker of bone formation, as it is pro-
duced by osteoblasts. PICP results from the
cleavage of a molecule of type I procollagen and
is a by-product of collagen synthesis.
Collagen type I is the most abundant protein
of bone, accounting for more than 90% of the
proteins of bone matrix.
The plasma concentration of PICP are de-
termined through the use of specific monoclonal
antibodies61,62.
PICP showed a high correlation with dynamic
histomorphometric parameters, but not with
static histomorphometric parameters nor with
other humeral markers of bone turn-over, in pre-
dialysis patients63.
In our experience, we found increased levels
of PICP in haemodialysis patients, but we did
not observe a significant correlation with any of
the histomorphometric parameters exami-
ned59;63 which is in accordance with the results
of Mazaferro et al64.
In patients already on dialysis, the results are
contradictory and difficult to interpret in an indi-
vidual patient. In a population of 18 patients on
haemodialysis, Hamdy et al. found inappro-
priately increased PICP levels in patients with
aluminium overload (38% of their patients)
whereas AP and osteocalcin levels were de-
creased, also indicating a relatively low specificity
and lack of responsiveness of PICP64,65.
BIOCHEMICAL SERUM MARKERS OF
BONE RESORPTION
Tartrate-resistant acid phosphatase
(TRAP) has been purposed as a potential marker
of bone resorption, because it is produced by
the osteoclasts, but the degree of specificity to
these cells is still not well defined, and a similar
fraction enzyme is produced by other cell types
(as we can see, for instance, in hairy cell leu-
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kaemia and Gaucher’s disease)66.
The physiological role of TRAP is still not
clear, even though it is recognised that it is di-
rectly evolved in bone resorption and that TRAP
dephosphorylates osteopontin and sialoprotein
(constituents of bone matrix)67.
TRAP represents the fraction of acid phos-
phatase that shows resistance, on its mobility
on acrylamide gel, to inhibition by tartrate. This
is a characteristic of the bone acid phosphatase
that was used in the past to separate it from the
other isoenzimes.
Immunoassays for the determination of
TRAP serum levels were developed, but clini-
cal data are still few, and the value of serum
TRAP levels in haemodialysis remains to be
clarified68-70.
Median TRAP serum levels were significantly
higher in dialysis patients with secondary
hyperparathyroid bone disease in comparison
with normal or low turnover bone disease pa-
tients71. Serum TRAP strongly correlated with
osteoclasts surface in dialysis patients71.
Pyridinoline cross-links of collagen exist
under two chemical forms: Hydroxylisylpyri-
dinoline (or pyridinoline - Pyr) and Lysylpyridi-
noline (or deoxypyridinoline - DPyr). Both are
present in bone and cartilage (in the former Dpyr
is the predominant type of pyridinoline)72.
The concentrations of Pyr and Dpyr have
been measured with specific policlonal and
monoclonal antibodies, and measured by Elisa
or HPLC in urine and later, in serum73.
These molecules are markers of type I and II
collagen breakdown and its urinary excretion
level has already been validated as an excellent
marker of the bone resorption in several meta-
bolic bone diseases72,74,75.
We have demonstrated, for the first time, that
serum Pyr concentrations can be reliably meas-
ured with an accurate competitive enzyme im-
munoassay76 in serum from dialysis patients,
and that these patients had markedly increased
serum Pyr levels compared with normal indi-
viduals59. In our 37 haemodialysis patients, the
highest values of serum Pyr were found in pa-
tients with the highest rate of bone resorption59.
Our results confirmed pyridinolines as good
markers of bone resorption. In fact, we observed
a good correlation between serum Pyr levels and
the number of osteoclasts/mm2 and the percen-
tage of bone covered by osteoclasts59. Serum
Pyd was correlated significantly better with bone
histology than iPTH or osteocalcin.
After transplantation, the urinary excretion of
Pyr and DPyr in normocalcemic patients was
more sensitive than iPTH and bAP in the diag-
nosis of secondary hyperparathyroidism77.
In opposition with these results, Bervoets and
col. could not find a significant difference in
deoxypyridinoline serum levels in 84 pre-dialy-
sis uraemic patients, with different bone histo-
logical disease44.
Type I collagen cross-linked telopeptide
ICTP is a collagen derivative that is released
during bone resorption, and contains cross-link-
ing molecules (pyridinolines).
Assays for ICTP using a policlonal antibody
have been developed but with disappointing clini-
cal results11;75. Its elimination rate depends on
the GFR and its serum levels respond poorly to
hormone replacement therapy after meno-
pause74.
We did not observe, in our dialysed patients,
a significant correlation between serum levels
of ICTP with any static or dynamic histomor-
phometric parameter, suggesting that ICTP is
not a sensitive marker of bone metabolism in
uraemia59. On the contrary, Mazzaferro et al
found ICTP serum levels correlated to serum
AP, bAP, iPTH and with some histomorphometric
indices of bone turnover, and point out ICTP as
a useful humoral marker of bone turnover in di-
alysis renal osteodystrophy64.
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ß2-microglobulin (ß2M) is a polypeptide of
a molecular weight of 11.810 daltons that accu-
mulates in the serum of uraemic patients. Since
the catabolism of ß2M takes place mainly in the
kidney, a progressive increase in its serum level
is observed with declining renal function, and
very high levels are observed in anuric patients
with end-stage renal failure78.
Serum ß2M levels correlated with serum tar-
taric resistant acid phosphatase in postmeno-
pausal women79;80.
 Particularly, those patients dialysed with a
low flux membrane and with a high vintage on
dialysis, present significantly increased ß2M
serum levels.
ß2M is the main constituent of amyloid de-
posits found in osteoarticular structures of
haemodialysis patients79.
We observed that patients with histological
high turnover bone disease had higher serum
levels than patients with normal/low turnover
bone disease and that serum ß2M levels were
correlated with serum markers of bone forma-
tion rate, namely osteocalcin and bone alkaline
phosphatase81.
In this prospective study, we also found a sig-
nificant correlation of ß2M levels with a specific
serum marker of bone resorption - serum free
pyridinoline - but not with intact PTH81. Lastly,
serum ß2M levels were negatively correlated
with osteoid volume in patients with high turno-
ver bone disease81.
Cytokines and local mediators of bone cells
activation
Different cytokines and growth factors are
directly involved in the activation and control of
the bone turnover cycle79,82.
The action of Interleukin-1 (IL-1) and tumour
necrosis factor α (TNF-α) are exerted on res-
ting osteoblasts, which cover the trabecular sur-
face. Secondarily, osteoblasts and stroma cells
of the bone marrow will participate in pre-osteo-
clast maturation and in the differentiation of these
cells into mature and activated osteoclasts by
Interleukin-6 (IL-6), Interleukin-11 (IL-11), gra-
nulocyte-macrophage colony stimulating factor
(GM-CSF) and macrophage colony stimulating
factor (M-CSF) secretion.
The balance between these cytokines and
their specific inhibitors is impaired in haemodi-
alysis patients83.
To study the role of some cytokines in bone
turnover process, we measured the circulating
levels of different cytokines and of their specific
inhibitors by Elisa, using serum of 17 chroni-
cally haemodialyzed patients.  Blood was drawn
at the same time as the bone biopsy was per-
formed, which allowed us to correlate it with the
bone histomorphometry results84.
In this study we established the presence of
increased levels of Interleukin-1, Interleukin-1
receptor antagonist, Interleukin-6 and Interleukin-
6 soluble receptor84.
Particularly interesting were the reverse re-
lationships observed, on one hand, between the
levels of Interleukin-1 receptor antagonist and
the osteoblastic surface and on the other, be-
tween the Interleukin-6 receptor / Interleukin-6
ratio (IL6-r/IL6) and the osteoclastic surface in
our 17 haemodialysis patients.
These results are consistent with the previ-
ously described stimulating effects of Interleukin-
1 on osteoblasts, suggesting that high serum
levels of Interleukin-1 receptor antagonist would
render the skeleton less sensitive to bone
resorption stimulation induced by Interleukin-182.
The reverse relationship between the Inter-
leukin-6 receptor / Interleukin-6 ratio and the
osteoclastic surface, which we observed in our
patients, is consistent with in vitro studies which
demonstrate the role of Interleukin-6 in promo-
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ting osteoclast differentiation and mature osteo-
clast activation85.
Other authors published results consistent
with ours, which suggest a participation of
Interleukin-6 in stimulating bone resorption, and
Interleukin-6 may be an action effector of PTH
and of other bone resorption stimulating agents85.
In bone sections from dialysis patients,
stained with antibodies to human interleukin-
1alpha, IL-6, IL-11, TNF-alpha, and TGF-beta,
intense staining was observed in fibrotic tis-
sue86. Immunorreactive TGF-beta and IL-6 was
also detected in osteoblasts and osteocytes,
suggesting a role of these cytokines in bone cell
activation and modulation86.
These findings support the hypothesis that
the cytokine / cytokine receptor / receptor an-
tagonist network play a relevant role in the
pathogenesis of renal osteodystrophy, and that
the serum levels of some of these local media-
tors might reflect the bone cells’ activity.
A new cytokine complex, the osteoprotegerin/
osteoprotegerin-ligand (OPG/OPGL), involved in
osteoclastogenesis and bone remodelling, was
discovered. OPG, is a soluble protein that inhi-
bits osteoclastic activation in vitro and bone
resorption in vivo87.
Another relevant cytokine with a direct role in
bone remodelling at cell level is the recently iden-
tified RANKL (receptor activator of NF-KB lig-
and). Osteoblasts, activated stromal cells, acti-
vated T cells and synovial fibroblasts express
RANKL, which is a type II trans-membrane pro-
tein found in the surface of the cells and as a
proteolytically released soluble form88.
Osteoclast progenitors express on their sur-
face the receptor for RANKL, which has been
named RANK (receptor activator of NF-KB). The
binding of RANKL to its RANK receptor results in
the differentiation and activation of osteoclasts,
from its progenitors, which express this receptor
on its surface89. On the contrary, OPG can inter-
act with RANKL, as a decoy receptor, and pre-
vent the binding of RANKL to RANK. In these cir-
cumstances, osteoclastogenesis activation is
inhibited89.
From the balance between RANKL and OPG
a greater or lesser osteoclastic activation and
maturation would result. The several systemic
(hormonal) and local (cytokines) stimuli of bone
remodelling may exert their actions via this
RANKL/RANK/OPG axis.
Coen and col. reported that, on average, OPG
serum levels were elevated in dialysis patients,
and correlated with the bone remodelling (low-
est levels were found in adynamic bone disease
patients)90. Similar results were described in 44
dialysis patients by Avbersek-Luznik et al, that
found OPG consistently increased in dialysis
patients, and 1.2 fold higher in patients with a
iPTH higher than 200 pg/mL versus those with
a iPTH lower that 200 pg/L91.
In opposition with these results, Haas et al.
found that OPG levels were significantly reduced
in patients with high turnover bone disease when
compared with normal or low turnover patients92.
In the 26 patients studied by these authors, and
submitted to a bone biopsy, OPG associated
with iPTH was proposed as a marker for non-
invasive diagnosis of renal osteodystrophy92.
These conflicting results underline the need
for more prospective and correctly designed
studies to evaluate the role of OPG as a marker
of bone remodelling in clinical practice.
CONCLUSION
From the above discussion, it is evident that
we are still looking for the ideal biochemical
marker of bone turnover.
Besides plasma iPTH, the immunoassays of
human bone alkaline phosphatase for bone for-
mation and of pyridinoline and TRAP for bone
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resorption seem to be the most sensitive and
specific serum markers of bone turnover. These
markers should be combined with serum iPTH
levels, with serum ß2M levels and with serum
aluminium levels.
The quantification of several cytokines and
growth factors involved in bone cell modulation
will probably acquire a relevant role in the diag-
nosis of renal osteodystrophy in the near future.
The evaluation of bone turnover should in-
clude a combination of different markers, so that
the balance between bone formation and bone
resorption can be adequately evaluated.
The combination of serum classical bio-
chemical markers with these new identified
cytokines will significantly increase the sensi-
bility and the specificity in the evaluation of the
bone turnover in uraemic patients.
Finally, in the individual patient, (and more fre-
quently that we had anticipated some years
ago), a bone biopsy is still needed to characte-
rize the bone remodelling and bone structure. A
bone biopsy is indicated particularly where pre-
vious aluminium overload is suspected, in symp-
tomatic patients with discordant biochemical
results, in the bone disease after transplanta-
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